上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Oxypeucedanin 纯度: 98.03%
Oxypeucedanin 是从 Angelica dahurica 中分离出来的呋喃香豆素衍生物。Oxypeucedanin 是一种选择性的开放通道阻滞剂,可抑制 hKv1.5 通道电流,IC50 值为 76 nM。Oxypeucedanin 延长心脏动作电位持续时间 (APD),是一种潜在的抗心律失常试剂。Oxypeucedanin 通过抑制癌细胞迁移来诱导细胞凋亡 (apoptosis )。
Oxypeucedanin Chemical Structure
CAS No. : 737-52-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥2020 | In-stock | |
10 mg | ¥3430 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
Oxypeucedanin 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Natural Product Library Plus
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Membrane Transporter/Ion Channel Compound Library
- Natural Product Library
- Anti-Cancer Compound Library
- Covalent Screening Library
- Anti-Cardiovascular Disease Compound Library
- Medicine Food Homology Compound Library
- Traditional Chinese Medicine Monomer Library
- Anti-Alzheimer’s Disease Compound Library
- Neurodegenerative Disease-related Compound Library
- Food-Sourced Compound Library
生物活性 |
Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC50 value of 76 nM. Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation[1]. Oxypeucedanin induces cell apoptosis through inhibition of cancer cell migration[2]. |
IC50 & Target |
IC50: HKv1.5 current; apoptosis[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
分子量 |
286.28 |
||||||||||||||||
Formula |
C16H14O5 |
||||||||||||||||
CAS 号 |
737-52-0 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (174.65 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务